Company Performance Metrics
Haig Keledjian: Founder & CEOPast Role: VG Life Sciences, Chief Executive Officer
Karen Newell Rogers: Chief ScientistPast Role: University of Colorado, Scientific Director of the CU Institute of Bioenergetics and Immunology
VG Life Sciences aims to improve and save lives through the development of transformative therapies for drug-resistant cancers and autoimmune diseases.
We are moving forward to achieve our vision through the research and development of drugs using two platform technologies, Targeted Peptide Technology (TPT) and Metabolic Disruption Technology
(MDT).
Our efforts on our revolutionary TPT drug, VG1177, for which we were issued a composition-of-matter patent (Patent No: US 8,957,031), are focused on accelerating progression from the research laboratory, to pre-clinical studies, and to clinical trials. The VG1177 peptide prevents the survival of pro-inflammatory cells that give rise to autoimmune diseases and other disorders.
We have completed a pre-investigational new drug meeting with the FDA (IND # 110820) and initiated preclinical work in November 2013 with our animal safety and toxicity study, a prerequisite for clinical trials.
Concurrently, we are continuing research at our laboratory at Texas A&M Health Sciences Center under the direction of VG Life Sciences’ Chief Scientist, Dr. M. Karen Newell-Rogers, Ph.D. Collaborating with research scientists from institutions around the country, Dr. Newell-Rogers is actively pursuing applications of VG1177.
